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Abstract 
Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical 
presentation, course, and outcome. The factors that determine the clinical variation of GBS are 
poorly understood which complicates the care and treatment of individual patients. The protocol of 
the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multi-centre 
cohort study that aims to identify the clinical and biological determinants and predictors of disease 
onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic 
criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if 
included within two weeks after onset of weakness. Information about demography, preceding 
infections, clinical features, diagnostic findings, treatment, course and outcome is collected. In 
addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard 
time points. The original aim was to include at least 1000 patients with a follow-up of 1-3 years. Data 
are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 
and by January 2017 included more than 1400 participants from 143 active centres in 19 countries 
across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise 
groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, 
electrophysiology, antecedent events, antibodies, genetics, prognostic modelling, treatment effects 
and long-term outcome of GBS. The IGOS will help to standardize the international collection of data 
and biosamples for future research of GBS.  
 
Keywords: Guillain-Barré syndrome, diagnosis, treatment, prognosis, outcome, biomarkers 
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Introduction 
Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy clinically characterized by a 
rapidly progressive symmetrical flaccid weakness of the limbs (van den Berg, et al., 2014; Willison, et 
al., 2016). The clinical presentation, course and outcome of GBS is variable. Some patients have mild 
weakness of the lower legs only, while others develop complete tetraplegia and respiratory failure 
requiring mechanical ventilation (van den Berg, et al., 2014; Willison, et al., 2016). Patients may have 
variant forms of GBS, including Miller Fisher syndrome (MFS), pure motor, paraparetic or pharyngeal-
cervical-brachial forms (van den Berg, et al., 2014; Wakerley, et al., 2014; Willison, et al., 2016). The 
electrophysiological findings are equally heterogeneous with subgroups of patients showing features 
of either demyelination or axonal degeneration (Hadden, et al., 1998; Ho, et al., 1995; Uncini and 
Kuwabara, 2012). The clinical recovery also varies: some patients recover spontaneously with no 
residual limitations, while others require mechanical ventilation for months and remain wheel chair 
bound for the rest of their lives or even die despite treatment (van den Berg, et al., 2014; Willison, et 
al., 2016). Independent of the GBS subtype, severity or predicted outcome, the standard treatment 
regimen for the past two decades has consisted of intravenous immunoglobulin (IVIg) or plasma 
exchange (PE) (Hughes, et al., 2007; Hughes, et al., 2014; Raphael, et al., 2012). Despite treatment, 
outcome of GBS is frequently poor since 2-5% of the patients die and 10-20% of patients remain 
severely disabled (Fokke, et al., 2014; Hughes, et al., 2007; Willison, et al., 2016). Outcome is even 
worse in low-income countries: in Bangladesh for example 85% of patients receive no treatment, 
15% die, and 30% remain severely disabled (Islam, et al., 2010). These findings show the need for 
more effective, personalized and accessible treatments worldwide.     
 The factors that determine the heterogeneity of GBS and that could provide a basis to 
personalize treatment are largely unknown. Previous studies observed an association between the 
clinical course in patients and the acute phase clinical characteristics or biomarkers such as 
electrophysiological subtype, preceding infections, anti-ganglioside antibodies, serum levels of IgG 
and albumin and genetic polymorphisms (Fokkink, et al., 2016; Geleijns, et al., 2006; Kuitwaard, et 
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al., 2009; Kusunoki, et al., 2008; van Koningsveld, et al., 2007; Walgaard, et al., 2010; Walgaard, et 
al., 2011; Walgaard, et al., 2016). However, most of these studies were retrospective, and the 
findings were derived from relatively small series or selected groups of patients with a short follow-
up period using a limited set of suboptimal outcome measures. In addition, the variety in inclusion 
criteria and methods used in these studies complicates comparing or combining collected data. 
Moreover, GBS varies considerably between geographical regions (Kuwabara and Yuki, 2013; Mori, et 
al., 2012; Willison, et al., 2016). Solving these problems requires a prospective study design with 
standardized collection of clinical data and biomaterials from a large group of well-defined GBS 
patients with a long follow-up period. The International GBS Outcome Study (IGOS) was initiated to 
collect the required clinical data and biosamples. After several organizational meetings, a final study 
protocol was prepared, and local investigators were invited to participate. IGOS is being conducted in 
collaboration with the Peripheral Nerve Society and Inflammatory Neuropathy Consortium (INC) 
(www.pnsociety.com/inflammatory-neuropathy-consortium/), an international organization of 
clinical neurologists and scientists involved in the investigation and care of patients with GBS.  
 
Study aim and objectives  
The overall aim of IGOS is to determine the clinical and biological determinants and predictors of the 
clinical course and outcome of GBS.  The objectives are: (1) to define the variation in clinical 
presentation, subtypes, progression and recovery of GBS in patients from a broad range of 
geographical areas, (2) to describe the current practice of diagnosis, treatment, and care for GBS, (3) 
to identify environmental and host factors that determine the disease onset and the variation in 
clinical course, treatment response and outcome, (4) to develop improved prognostic models to 
predict the clinical course and outcome in individual patients, and (5) to facilitate the collection of 
standardized and relevant data and biosamples for future studies of GBS.  
 
Methods and Materials 
Study design  
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IGOS is an international, prospective, observational, multi-center cohort study.  It uses a predefined 
protocol to collect data regarding baseline characteristics, clinical presentation and course, 
electrophysiology, diagnosis, treatment and outcome during a follow-up of 1 year with the possibility 
to extend the follow-up to 2 or 3 years (Figure 1). The protocol specifies the timing of the collection 
of biosamples, including blood for DNA and serum studies and cerebrospinal fluid (CSF). Predictive 
models for the clinical course and outcome will be based on results collected in the first two weeks. 
The first 1000 participants will constitute a derivation cohort. The next 500 or more patients will 
provide a validation cohort. 
 
Inclusion and exclusion criteria for patients 
Inclusion requires fulfilling the following criteria:  
1. The diagnostic criteria for GBS of the National Institute of Neurological Disorders and Stroke 
(NINDS) (See supplement 1), or one of the variants of GBS, including the MFS and overlap 
syndromes (Asbury and Cornblath, 1990; Sejvar, et al., 2011; Wakerley, et al., 2014).  
2. Entry within two weeks of onset of weakness (or other symptoms attributed to GBS). 
3. Opportunity to continue a follow-up for at least one year. 
4. Informed consent of the participant or, for children, the parents or legal guardians.  
The aim is to enroll patients representing the full spectrum of GBS. There are no exclusion criteria, 
and all patients with GBS or its variants, including MFS and overlap forms, may participate, regardless 
of age, disease severity, or treatment.  
 
IGOS data- and biobank 
Baseline, clinical and treatment data  
We collect baseline data about the patients’ demography, co-morbidity, family history and 
antecedent events. In addition, we record the first clinical symptoms and signs of GBS, the timing and 
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key features of the diagnosis, hospital transfers, neurological examination findings and the clinical 
course. The severity and distribution of clinical manifestations of GBS will be documented in detail, 
including cranial nerve deficits, limb weakness using the MRC sum score (Kleyweg, et al., 1991) and 
Rasch-built MRC score (Vanhoutte, et al., 2012), sensory deficits, ataxia, limb tendon reflexes, GBS 
disability scale (Hughes, et al., 1978), pain, autonomic dysfunction, respiratory failure, and associated 
medical complications. In addition, we record the occurrence of treatment related fluctuations and 
transitions to chronic inflammatory demyelinating polyneuropathy (CIDP) (Ruts, et al., 2010). From 4 
weeks onward, we collect the following clinical outcome measures: Overall Neuropathy Limitation 
Scale (ONLS) (Graham and Hughes, 2006), Rasch-built Overall Disability Score (R-ODS) (van Nes, et 
al., 2011), Fatigue Severity Scale (FSS) (and Rasch-built FSS) (van Nes, et al., 2009) and the EuroQol 
EQ-5D health questionnaire (Brooks, 1996) (Figure 1). A full neurological examination will be 
performed at study entry and after 1 week, 2 weeks, 4 weeks, 26 (± 2) weeks and 52 (± 4) weeks. 
Participants still in hospital at 8 (± 1) weeks and 13 (± 1) weeks will be examined but those who have 
been discharged have only a telephone assessment of the GBS disability scale, ONLS, R-ODS, FSS and 
EuroQoL EQ-5D. All patient reported outcome measures have been translated (and back translated) 
into the language of the participants. We collect detailed information about the treatment for GBS 
including the type, timing, regimen and side-effects of treatment, admission to intensive care, and 
start and end of mechanical ventilation. If a patient dies, we document the timing and cause of 
death. 
 
Electrophysiology data 
We collect the results of the routine diagnostic electrophysiological examinations, including the raw 
data and the local investigators’ interpretation and classification of the subtype, including acute 
inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute 
motor-sensory axonal neuropathy (AMSAN), inexcitable nerves, and equivocal or normal results. The 
study protocol recommends performing electrophysiological studies according to a predefined 
standard format (see Supplement 2). Some clinics routinely perform a second diagnostic nerve 
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conduction study and we collect these results when available. We document locally used normative 
values and standard electrophysiology protocols. 
 
Blood samples 
We collect blood and CSF samples according to a predefined schedule (Figure 1). Blood samples 
provide serum and DNA. The protocol specifies that the first serum sample is to be collected before 
the start of treatment, although in some patients treatment is being initiated before study entry 
(e.g., when patients transfer to a center participating in IGOS after treatment at a local community 
hospital). Blood samples are frozen and stored at -80◦C (or initially stored -20◦C for a maximum of 6 
months) at the local center or at the center of the country coordinator, and transported on dry ice to 
a central biobank, at Erasmus MC in Rotterdam, the Netherlands, with a reserve biobank at the 
University of Glasgow, Scotland, UK.   
 
Cerebrospinal fluid samples 
If participants have a routine lumbar puncture to examine CSF for diagnostic studies, we keep an 
aliquot for biomarker studies. In centers participating in an advanced proteomics study, an extra 
aliquot is sampled (Teunissen, et al., 2009). This study requires centrifugation of the CSF sample 
within one hour after the lumbar puncture. The supernatant (without pellet) is removed and 
immediately stored in a polystyrene tube at -20 ◦C until being transferred to the country coordinating 
center and stored at -80 ◦C. This optional research module requires additional informed consent. 
 
Extended follow-up of two and three years 
The time course of nerve regeneration and clinical recovery in GBS is unclear. Some patients 
continue to improve even after one year (Dhar, et al., 2008; Rudolph, et al., 2008). To determine the 
further recovery and long-term residual deficits, there is an optional long-term follow-up research 
module with a telephone assessment at 2 years (104 ± 4 weeks) and 3 years (156 ± 4 weeks) after 
onset. The data collected then include the GBS disability score, ONLS, R-ODS, FSS (and Rasch-FSS), 
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and EuroQoL EQ-5D. Severely affected patients may have more extensive evaluation including 
neurological examination at each visit. The long-term follow-up requires additional informed 
consent.  
 
Children with GBS 
Children with GBS differ from adult patients regarding their preceding infections, clinical features, 
GBS subtype, treatment and outcome (Korinthenberg, et al., 2007; Roodbol, et al., 2011). In children 
it is more difficult to obtain biosamples and the adult outcome measures have not all been validated. 
For this reason we are using an adapted protocol for children with age-dependent sampling of 
biomaterials and clinical assessment scales.  
 
Data collection 
We have developed a web-based data entry system that meets the standards of security and privacy 
of Erasmus MC, the host institution. The local investigators use this website to enter the data. The 
information stored is strictly anonymous. All participants have a unique code for use throughout the 
study. The quality of the collected data is controlled regularly by the IGOS Coordinating Center 
according to protocol and additional controls will be conducted by the IGOS Expertise Groups.    
 
Sample size 
The extent of the clinical variation of GBS in the world is currently unknown and limits the possibility 
to conduct a power calculation. There is only circumstantial evidence available to estimate the 
required size of the study. It is recommended for the development of predictive logistic regression 
models that the smallest outcome group should include at least 100 patients (Vergouwe, et al., 
2005). Previous therapeutic trials with GBS defined poor outcome as a GBS disability score of >2 (not 
being able to walk unaided or worse) (Hughes, et al., 1978). In treatment trials about 10-15% of 
participants have had a poor outcome after one year (Hughes, et al., 2007; van Koningsveld, et al., 
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2007). If we aim to include at least 100 participants with a poor outcome defined in this way, the 
whole study will need at least 1000 participants. Therefore this is the minimum size of the derivation 
cohort to identify new clinical and biological markers to predict poor outcome or evaluate previously 
described prognostic factors. In addition, we collect an independent validation cohort of at least 500 
patients to validate any new clinical or biomarkers that emerge from the derivation cohort.     
 
Statistical analyses 
Descriptive statistics are used to analyze the clinical data.  We will develop prognostic models to 
evaluate the use of biomarkers and clinical characteristics to predict outcome in clinical practice 
according to our previously published statistical approaches (van Koningsveld, et al., 2007; Walgaard, 
et al., 2010; Walgaard, et al., 2011). The association between putative prognostic factors and 
outcome variables will be analyzed using univariate and multivariable logistic regression models. If 
two similar variables are equally associated with outcome, the variable most easily obtainable in 
clinical practice will be selected. We will quantify model performance with respect to discrimination 
(area under receiver operating characteristic curve). Multivariable regression coefficients will be used 
to develop new prognostic models for GBS. 
 
IGOS Consortium and IGOS Research Policy Agreement 
IGOS is conducted by the IGOS Consortium which consists of (1) the members of the Steering 
Committee, (2) the staff of the Coordinating Center at Erasmus MC, Rotterdam, the Netherlands, (3) 
the Country Coordinators and (4) their networks of local investigators (see Appendix). To be able to 
participate in IGOS and to become a member of the IGOS Consortium all participants signed the IGOS 
Consortium Agreement which defined the conduct of the study. All members of the IGOS Consortium 
can apply to the Steering Committee to use the IGOS data/biobank to address specific research 
questions. Research projects are also being conducted by the Expertise Groups, consisting of 
members of the IGOS Consortium and additional researchers if external expertise is required.      
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Ethical regulations 
The IGOS received approval from the Medical Ethics Review Committee of the Erasmus MC Medical 
University Rotterdam in 2012. Each participating center also had approval from their local 
Institutional Review Board (IRB). The IGOS is being conducted according to the principles of the 
Declaration of Helsinki (59th WMA General Assembly, Seoul, October 2008) and the Medical Research 
Involving Human Subjects (WMO). The procedures set out in this protocol were designed to ensure 
that the investigators abide by the principles of the GCP guidelines of the European Community (ICH 
topic E6, CPMP/ICH/135/95, Directive 2001/20/EC) in the conduct, evaluation and documentation of 
this study. Inclusion in IGOS requires informed consent from each participant or their legal 
representative. IGOS was registered before the start of the study at ClinicalTrials.gov (NCT01582763).  
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Discussion 
IGOS started in May 2012 and in June 2015 IGOS had enrolled 1000 patients who will form the 
derivation cohort (Figure 2). By January 2017, more than 1400 patients with GBS had been included 
in IGOS by 143 active sites from 19 countries across five continents (Figure 3). We are continuing to 
recruit more patients to complete the independent validation cohort, and anticipate enrollment of 
1500 patients by July 2017.  
IGOS has important advantages over previous observational studies of GBS. First, IGOS already 
includes the largest number of prospectively collected patients with a confirmed diagnosis of GBS. 
Second, there was no selection of patients based on age, clinical subtype or severity, aiming to 
investigate the full range of variants within the spectrum of GBS. Third, we collected data from 
patients from various geographical regions, including high- and low-income countries using the same 
protocol and will be able to compare and contrast various attributes of the condition worldwide. 
Fourth, IGOS has a long follow-up period and uses several well-defined and validated outcome 
measures to assess the long-term outcome of GBS. Fifth, we are collecting biosamples prospectively 
according to the protocol at recruitment and follow-up visits coinciding with clinical assessments. We 
will use these samples to study preceding infections, antibodies to peripheral nerves and other 
immunological factors, pharmacokinetics, genetic factors, and other potential biomarkers for 
correlation with clinical features. Because of these advantages, IGOS will provide the most extensive 
research data- and biobank of GBS patients collected so far. This will enhance our understanding of 
the pathogenesis and the individual clinical course, prognosis, treatment response and outcome. The 
overall aim is to develop more effective personalized treatment regimens based on a better 
understanding of the variation of the disease. 
IGOS has already enhanced international collaboration in research into the cause and treatment of 
GBS by strengthening international networks. Expertise Groups will be formed on various topics 
including (1) emerging preceding events related to GBS, (2) diagnostic criteria and protocols for GBS, 
(3) electrophysiological subtypes of GBS, (4) biological determinants including genetic 
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polymorphisms, preceding infections and serum antibodies in the pathogenesis of GBS and its 
subtype, (5) biomarkers for monitoring treatment, pharmacokinetics and disease activity, (6) 
validating and improving outcome measures, (7) long-term outcome, (8) prediction of prognosis, and 
(9) improving treatment.  
By providing an infrastructure for standardized collection of data and biomaterials, IGOS will facilitate 
international research projects on emerging infections associated with GBS, such as the recent 
outbreak of Zika virus infection (Cao-Lormeau, et al., 2016; Parra, et al., 2016). This infrastructure will 
also help to record other emerging preceding events that have been previously related to the 
development of GBS, including vaccinations. Our aim is also to use the international expertise 
involved in IGOS and the collected materials to compare and standardize assays for relevant 
biomarkers in GBS including preceding infections, antibodies, genetic polymorphisms and 
pharmacokinetic analysis. The extensive recording of the clinical course and outcome at serial visits 
during long-term follow-up provides a unique opportunity for international validation of outcome 
measures that so far have been developed in limited regions only. The IGOS data- and biobank 
provide an easily accessed source of control natural history data for modelling studies and 
comparison with patients treated with novel treatment regimens. One ongoing study is already 
comparing one with two courses of IVIg in patients with a poor predicted outcome (International 
Second IVIg Dose GBS Study). A second observational study within IGOS is comparing IVIg treatment 
with supportive care alone for patients with initially mild GBS. IGOS provides an exciting opportunity 
to support future clinical trials. The consortium is open to collaboration with other academic partners 
and with pharmaceutical companies interested in improving the treatment of GBS.  
 
Funding 
The IGOS study protocol was developed without external financial support. The development of a 
web-based data entry support was supported by funding from the GBS-CIDP Foundation 
International (https://www.gbs-cidp.org/). Additional funding to support the conduct of IGOS for 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
specific countries or projects was received from gain (http://www.gaincharity.org.uk/), Erasmus MC, 
Rotterdam, The Netherlands, University of Glasgow, Glasgow, United Kingdom, Grifols, CSL Behring, 
Shire Pharmaceuticals and Annexon. IGOS is scientifically independent, and the funding agencies 
have no influence on the study and infrastructure design of IGOS, nor on the collection, statistical 
analysis and interpretation of the data collected in IGOS, nor on the writing, publication of 
manuscripts or other presentations based on these data.   
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Figures 
Figure 1. Time schedule of research protocol for the IGOS database and biobank.  
 
 
 
Legend figure 1.  
The filled blocks refer to obligatory studies, the striped to optional substudies. The timeline 
represents the follow-up period after study entry in weeks. The first 2 weeks focus on collecting data 
and biomaterials to predict the clinical course and outcome in the period after 2 weeks. Blood 
samples are obtained as indicated for serial serological studies and for DNA extraction. Routine 
diagnostic electrophysiology will be conducted in the first or second week, and as an optional study 
at 4 weeks. * At 8 weeks and 13 weeks patients admitted at the hospital will have a full examination 
and serum sampling but discharged patients will have telephone assessment only and no serum 
sampling. 
1 Patient reported outcome measures (PROM) used are R-ODS, FSS, Rasch-FSS, EuroQol EQ-5D.  
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Supplement Table 1: Diagnostic criteria for Guillain-Barré syndrome (GBS) 
 
Features required for diagnosis 
Progressive weakness in both arms and legs (might start with weakness only in the legs) 
Areflexia (or decreased tendon reflexes) 
 
Features that strongly support diagnosis 
Progression of symptoms over days to 4 weeks 
Relative symmetry of symptoms 
Mild sensory symptoms or signs 
Cranial nerve involvement, especially bilateral weakness of facial muscles 
Autonomic dysfunction 
Pain (often present) 
High concentration of protein in CSF 
Typical electrodiagnostic features 
 
Features that should raise doubt about the diagnosis 
Severe pulmonary dysfunction with limited limb weakness at onset 
Severe sensory signs with limited weakness at onset 
Bladder or bowel dysfunction at onset 
Fever at onset 
Sharp sensory level 
Slow progression with limited weakness without respiratory involvement (consider subacute 
inflammatory demyelinating polyneuropathy or CIDP) 
Marked persistent asymmetry of weakness 
Persistent bladder or bowel dysfunction 
Increased number of mononuclear cells in CSF (>50×10E6/L) 
Polymorphonuclear cells in CSF 
 
Legend supplement Table 1 
Adapted from Asbury and Cornblath et al. (Asbury and Cornblath, 1990) 
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Supplement Table 2: Recommended protocol for routine diagnostic electrophysiology  
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Motor nerve conductions studies  
 Responsive
(yes/no) 
DML
(ms) 
Distal CMAP amplitude 
(baseline-peak) (mV) 
Prox. CMAP ampl. I 
(baseline-peak) (mV) 
Prox. CMAP ampl. II
(baseline-peak) (mV) 
NCV I
(m/s) 
NCV II
(m/s) 
Minimal F-wave 
latency(>10)(ms) 
H-M lat
(ms) 
1. Median nerve –APB (nd) X X X X X X  
2. Ulnar nerve- ADM (nd) X X X X X X X X  
3. Peroneal nerve-EDB (nd)) X X X X X X X X  
4. Other nerve* X X X X X X X X  
5. H-reflex m. soleus (nd) X X 
 
Sensory nerve conductions studies  
 Responsive
(yes/no) 
DSL 
(ms) 
Distal SNAP amplitude 
(baseline-peak) (μV) 
Prox. SNAP ampl. I 
(baseline-peak) (μV) 
Prox. SNAP ampl. II
(baseline-peak)(μV) 
NCV I
(m/s) 
NCV II
(m/s) 
NCV III
(m/s) 
1. Median nerve- dig II (nd) X X X X X X
2. Ulnar nerve- dig V (nd) X X X X X X X X
3. Sural nerve (nd) X X X X X
4. Optional radial nerve(nd) X X X X X X
 
 
Optional needle EMG  
 Fibrilations
(yes/no) 
Positive sharp waves 
(yes/no) 
Polyphasic MU 
(yes/no) 
Increased size MU
(yes/no) 
Decreased MU recruitment 
(yes/no) 
1. Dorsal Interosseus I muscle  
2. Anterior tibial muscle  
3. Proximal arm muscle 
(deltoid or biceps muscle) 
 
4. Proximal leg muscle 
(vastus lateralis muscle) 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
 
Legend supplement Table 2. 
Local investigators are free to conduct the nerve conduction studies according to their local routine standards but recommended in IGOS is to 
perform a complete electrophysiological examination at two separate time points: the first within 7 days of admission or registration in IGOS, 
and the second at four weeks after admission or registration in IGOS. The collected data should include sensory studies in legs and arms (3-4 
nerves), motor studies with F waves (3-4 nerves), tibial H-reflexes and EMG of a proximal and distal muscle in an arm and leg. Normative data 
and pictures of the waveforms will also be included in the report. 
nd = non-dominant side 
*    = other nerve (median, ulnar or peroneal nerve on dominant-side or tibial nerve on dominant side) (Uncini and Kuwabara, 2012) 
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